Comment from Amneal Pharmaceuticals LLC

Summary: Amneal Pharmaceuticals LLC supports the FDA's decision not to include GLP-1 receptor agonists on the 503B Bulks List. The company argues that these drugs are widely available, and adding them to the list would pose patient safety risks, undermine the statutory framework for compounding, and discourage investment in domestic manufacturing.